ReviewAging and disease2024
Targeting the Ophthalmic Diseases Using Extracellular Vesicles 'Exosomes': Current Insights on Their Clinical Approval and Present Trials.
Review in Aging and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.International journal of molecular sciences · 2026Review
- Recent advances in engineered exosome-based therapies for ocular vascular disease.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ophthalmic diseases encompass a diverse range of conditions, each necessitating tailored treatment strategies. In the realm of ophthalmic research and therapeutic interventions, various subtypes of exosomes are being explored for their regenerative, neuroprotective, and anti-inflammatory properties. Exosomes have garnered increasing attention as promising therapeutic vehicles due to their natural role in cell-to-cell communication and targeted delivery capabilities. Derived from cells, these small vesicles facilitate the transportation of numerous molecules between cells, offering advantages such as low immunogenicity, stability, and precise cell targeting. These inherent qualities make exosomes an enticing avenue for advancing treatment options for ophthalmic diseases. While ongoing research and clinical applications continue to evolve, several exosome subtypes have demonstrated potential for addressing various ophthalmic conditions, including glaucoma, age-related macular degeneration, retinal degenerative disorders, and ocular inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.